nodes	percent_of_prediction	percent_of_DWPC	metapath
Bevantolol—ADRA1A—polycystic ovary syndrome	0.546	0.627	CbGaD
Bevantolol—ADRB2—polycystic ovary syndrome	0.325	0.373	CbGaD
Bevantolol—Papaverine—PDE3B—polycystic ovary syndrome	0.00294	0.329	CrCbGaD
Bevantolol—Tamsulosin—ADRA1D—polycystic ovary syndrome	0.000943	0.106	CrCbGaD
Bevantolol—Tamsulosin—ADRA1B—polycystic ovary syndrome	0.000804	0.0901	CrCbGaD
Bevantolol—Tamsulosin—ADRA1A—polycystic ovary syndrome	0.000541	0.0607	CrCbGaD
Bevantolol—Carvedilol—ADRA1D—polycystic ovary syndrome	0.000483	0.0541	CrCbGaD
Bevantolol—Carvedilol—ADRB3—polycystic ovary syndrome	0.000434	0.0486	CrCbGaD
Bevantolol—Carvedilol—ADRA1B—polycystic ovary syndrome	0.000412	0.0462	CrCbGaD
Bevantolol—Esmolol—ADRB2—polycystic ovary syndrome	0.000366	0.041	CrCbGaD
Bevantolol—Propranolol—ADRB3—polycystic ovary syndrome	0.00033	0.037	CrCbGaD
Bevantolol—Bisoprolol—ADRB2—polycystic ovary syndrome	0.000311	0.0348	CrCbGaD
Bevantolol—Carvedilol—VEGFA—polycystic ovary syndrome	0.000293	0.0329	CrCbGaD
Bevantolol—Carvedilol—ADRA1A—polycystic ovary syndrome	0.000277	0.0311	CrCbGaD
Bevantolol—Metoprolol—ADRB2—polycystic ovary syndrome	0.000249	0.0279	CrCbGaD
Bevantolol—Carvedilol—ADRB2—polycystic ovary syndrome	0.000165	0.0185	CrCbGaD
Bevantolol—Carvedilol—CYP1A1—polycystic ovary syndrome	0.000141	0.0159	CrCbGaD
Bevantolol—Propranolol—ADRB2—polycystic ovary syndrome	0.000125	0.0141	CrCbGaD
Bevantolol—Propranolol—CYP1A1—polycystic ovary syndrome	0.000108	0.0121	CrCbGaD
Bevantolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—ADRB2—polycystic ovary syndrome	8.74e-05	0.000723	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—ADRA1D—polycystic ovary syndrome	8.71e-05	0.000721	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	8.68e-05	0.000719	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	8.67e-05	0.000717	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—PLEKHG5—polycystic ovary syndrome	8.6e-05	0.000712	CbGpPWpGaD
Bevantolol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—GHRL—polycystic ovary syndrome	8.54e-05	0.000707	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	8.49e-05	0.000703	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	8.48e-05	0.000702	CbGpPWpGaD
Bevantolol—ADRA1A—GPCRs, Class A Rhodopsin-like—ADRB2—polycystic ovary syndrome	8.25e-05	0.000683	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—PTAFR—polycystic ovary syndrome	8.18e-05	0.000677	CbGpPWpGaD
Bevantolol—ADRB1—GPCR ligand binding—GHRL—polycystic ovary syndrome	8.04e-05	0.000665	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—FLT4—polycystic ovary syndrome	7.94e-05	0.000658	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—PTGER3—polycystic ovary syndrome	7.94e-05	0.000657	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—LHCGR—polycystic ovary syndrome	7.94e-05	0.000657	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—ADRA1D—polycystic ovary syndrome	7.94e-05	0.000657	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—FSHR—polycystic ovary syndrome	7.91e-05	0.000654	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—PDE3B—polycystic ovary syndrome	7.88e-05	0.000653	CbGpPWpGaD
Bevantolol—ADRB2—GPCR ligand binding—GHRL—polycystic ovary syndrome	7.86e-05	0.000651	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—FLT4—polycystic ovary syndrome	7.77e-05	0.000643	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—FSHR—polycystic ovary syndrome	7.74e-05	0.00064	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—ADRA1B—polycystic ovary syndrome	7.72e-05	0.000639	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—PDE3B—polycystic ovary syndrome	7.71e-05	0.000638	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—PTAFR—polycystic ovary syndrome	7.43e-05	0.000615	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	7.23e-05	0.000599	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—ADRA1D—polycystic ovary syndrome	7.21e-05	0.000597	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—FSHR—polycystic ovary syndrome	7.18e-05	0.000594	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	7.07e-05	0.000586	CbGpPWpGaD
Bevantolol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRB2—polycystic ovary syndrome	7.07e-05	0.000585	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	7.03e-05	0.000581	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—FSHR—polycystic ovary syndrome	7.02e-05	0.000581	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	7.01e-05	0.00058	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	6.96e-05	0.000576	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—NPB—polycystic ovary syndrome	6.94e-05	0.000575	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—LHB—polycystic ovary syndrome	6.88e-05	0.000569	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	6.81e-05	0.000564	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—NPB—polycystic ovary syndrome	6.79e-05	0.000562	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—LHB—polycystic ovary syndrome	6.73e-05	0.000557	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	6.72e-05	0.000557	CbGpPWpGaD
Bevantolol—ADRB1—GPCR ligand binding—ADRB2—polycystic ovary syndrome	6.65e-05	0.000551	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	6.58e-05	0.000544	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	6.57e-05	0.000544	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR ligand binding—GHRL—polycystic ovary syndrome	6.5e-05	0.000538	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—SCT—polycystic ovary syndrome	6.45e-05	0.000534	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—FLT4—polycystic ovary syndrome	6.43e-05	0.000532	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	6.42e-05	0.000532	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—FSHR—polycystic ovary syndrome	6.4e-05	0.00053	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—PDE3B—polycystic ovary syndrome	6.38e-05	0.000528	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—ADRB3—polycystic ovary syndrome	6.32e-05	0.000523	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—SCT—polycystic ovary syndrome	6.31e-05	0.000522	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	6.28e-05	0.00052	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—LHB—polycystic ovary syndrome	6.25e-05	0.000517	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—ADRB3—polycystic ovary syndrome	6.18e-05	0.000512	CbGpPWpGaD
Bevantolol—ADRB1—GPCR ligand binding—GNAS—polycystic ovary syndrome	6.17e-05	0.000511	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	6.15e-05	0.000509	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	6.14e-05	0.000508	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—LHB—polycystic ovary syndrome	6.11e-05	0.000506	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—GNRH1—polycystic ovary syndrome	6.11e-05	0.000505	CbGpPWpGaD
Bevantolol—ADRB2—GPCR ligand binding—GNAS—polycystic ovary syndrome	6.03e-05	0.000499	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	6.02e-05	0.000498	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—GNRH1—polycystic ovary syndrome	5.97e-05	0.000494	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—SCT—polycystic ovary syndrome	5.85e-05	0.000485	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—FSHR—polycystic ovary syndrome	5.81e-05	0.000481	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—LHCGR—polycystic ovary syndrome	5.8e-05	0.00048	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—PTGER3—polycystic ovary syndrome	5.8e-05	0.00048	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—SCT—polycystic ovary syndrome	5.73e-05	0.000474	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—PTGER3—polycystic ovary syndrome	5.67e-05	0.000469	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—LHCGR—polycystic ovary syndrome	5.67e-05	0.000469	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	5.63e-05	0.000466	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—NPB—polycystic ovary syndrome	5.62e-05	0.000465	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	5.58e-05	0.000462	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—LHB—polycystic ovary syndrome	5.57e-05	0.000461	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	5.46e-05	0.000452	CbGpPWpGaD
Bevantolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	5.45e-05	0.000451	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	5.44e-05	0.00045	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—PTAFR—polycystic ovary syndrome	5.42e-05	0.000449	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR ligand binding—ADRB2—polycystic ovary syndrome	5.38e-05	0.000446	CbGpPWpGaD
Bevantolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	5.34e-05	0.000442	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—PTAFR—polycystic ovary syndrome	5.3e-05	0.000439	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—ADRA1D—polycystic ovary syndrome	5.26e-05	0.000436	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—SCT—polycystic ovary syndrome	5.22e-05	0.000432	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—ADRA1D—polycystic ovary syndrome	5.15e-05	0.000426	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—ADRA1B—polycystic ovary syndrome	5.12e-05	0.000424	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—ADRB3—polycystic ovary syndrome	5.12e-05	0.000423	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	5.08e-05	0.000421	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—LHB—polycystic ovary syndrome	5.05e-05	0.000418	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—ADRA1B—polycystic ovary syndrome	5.01e-05	0.000414	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR ligand binding—GNAS—polycystic ovary syndrome	4.99e-05	0.000413	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—INHBB—polycystic ovary syndrome	4.99e-05	0.000413	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	4.98e-05	0.000412	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—GNRH1—polycystic ovary syndrome	4.94e-05	0.000409	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—INHBB—polycystic ovary syndrome	4.88e-05	0.000404	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—SCT—polycystic ovary syndrome	4.74e-05	0.000392	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—PTGER3—polycystic ovary syndrome	4.69e-05	0.000388	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—LHCGR—polycystic ovary syndrome	4.69e-05	0.000388	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—PDE3B—polycystic ovary syndrome	4.66e-05	0.000385	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—PDE3B—polycystic ovary syndrome	4.56e-05	0.000377	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—GHRL—polycystic ovary syndrome	4.54e-05	0.000376	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	4.52e-05	0.000374	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—GHRL—polycystic ovary syndrome	4.44e-05	0.000368	CbGpPWpGaD
Bevantolol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	4.41e-05	0.000365	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—PTAFR—polycystic ovary syndrome	4.39e-05	0.000363	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—ADRA1D—polycystic ovary syndrome	4.26e-05	0.000352	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—FSHR—polycystic ovary syndrome	4.24e-05	0.000351	CbGpPWpGaD
Bevantolol—ADRB1—GPCR ligand binding—POMC—polycystic ovary syndrome	4.15e-05	0.000344	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—FSHR—polycystic ovary syndrome	4.15e-05	0.000343	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—ADRA1B—polycystic ovary syndrome	4.14e-05	0.000343	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—GHRL—polycystic ovary syndrome	4.12e-05	0.000341	CbGpPWpGaD
Bevantolol—ADRB2—GPCR ligand binding—POMC—polycystic ovary syndrome	4.06e-05	0.000336	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—INHBB—polycystic ovary syndrome	4.04e-05	0.000334	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—GHRL—polycystic ovary syndrome	4.03e-05	0.000334	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—RACGAP1—polycystic ovary syndrome	3.99e-05	0.00033	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—RACGAP1—polycystic ovary syndrome	3.9e-05	0.000323	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—ADRA1A—polycystic ovary syndrome	3.88e-05	0.000321	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—ADRA1A—polycystic ovary syndrome	3.8e-05	0.000314	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—FST—polycystic ovary syndrome	3.78e-05	0.000313	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—PDE3B—polycystic ovary syndrome	3.77e-05	0.000312	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	3.76e-05	0.000311	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—ADRB3—polycystic ovary syndrome	3.73e-05	0.000309	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—FST—polycystic ovary syndrome	3.7e-05	0.000306	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—LHB—polycystic ovary syndrome	3.69e-05	0.000305	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—GHRL—polycystic ovary syndrome	3.67e-05	0.000304	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—ADRB3—polycystic ovary syndrome	3.65e-05	0.000302	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—LHB—polycystic ovary syndrome	3.61e-05	0.000299	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—GNRH1—polycystic ovary syndrome	3.61e-05	0.000299	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—GNRH1—polycystic ovary syndrome	3.53e-05	0.000292	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—AKR1C1—polycystic ovary syndrome	3.49e-05	0.000289	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—GNAS—polycystic ovary syndrome	3.49e-05	0.000289	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—SCT—polycystic ovary syndrome	3.46e-05	0.000286	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—FSHR—polycystic ovary syndrome	3.43e-05	0.000284	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—AKR1C1—polycystic ovary syndrome	3.42e-05	0.000283	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—ADRB2—polycystic ovary syndrome	3.41e-05	0.000283	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—GNAS—polycystic ovary syndrome	3.41e-05	0.000282	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—SCT—polycystic ovary syndrome	3.38e-05	0.00028	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR ligand binding—POMC—polycystic ovary syndrome	3.36e-05	0.000278	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—GHRL—polycystic ovary syndrome	3.34e-05	0.000276	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—MTNR1B—polycystic ovary syndrome	3.3e-05	0.000273	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—FGF18—polycystic ovary syndrome	3.24e-05	0.000268	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—MTNR1B—polycystic ovary syndrome	3.23e-05	0.000267	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—RACGAP1—polycystic ovary syndrome	3.23e-05	0.000267	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—RBP4—polycystic ovary syndrome	3.21e-05	0.000266	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—FGF18—polycystic ovary syndrome	3.17e-05	0.000262	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—GNAS—polycystic ovary syndrome	3.17e-05	0.000262	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—RBP4—polycystic ovary syndrome	3.14e-05	0.00026	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—GNAS—polycystic ovary syndrome	3.1e-05	0.000256	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—FST—polycystic ovary syndrome	3.06e-05	0.000253	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	3.04e-05	0.000252	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—ADRB3—polycystic ovary syndrome	3.02e-05	0.00025	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—YAP1—polycystic ovary syndrome	3e-05	0.000248	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—LHB—polycystic ovary syndrome	2.99e-05	0.000247	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—GAB1—polycystic ovary syndrome	2.96e-05	0.000245	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—YAP1—polycystic ovary syndrome	2.94e-05	0.000243	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—GNRH1—polycystic ovary syndrome	2.92e-05	0.000242	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—GAB1—polycystic ovary syndrome	2.9e-05	0.00024	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—INSR—polycystic ovary syndrome	2.83e-05	0.000234	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—AKR1C1—polycystic ovary syndrome	2.83e-05	0.000234	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—GNAS—polycystic ovary syndrome	2.82e-05	0.000233	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—SCT—polycystic ovary syndrome	2.8e-05	0.000232	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—INSR—polycystic ovary syndrome	2.77e-05	0.000229	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—ADRB2—polycystic ovary syndrome	2.76e-05	0.000229	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	2.69e-05	0.000223	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—MTNR1B—polycystic ovary syndrome	2.67e-05	0.000221	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	2.65e-05	0.000219	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—AKR1C3—polycystic ovary syndrome	2.63e-05	0.000218	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—FGF18—polycystic ovary syndrome	2.62e-05	0.000217	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—PGR—polycystic ovary syndrome	2.62e-05	0.000217	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—RBP4—polycystic ovary syndrome	2.6e-05	0.000215	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—TNRC6B—polycystic ovary syndrome	2.59e-05	0.000214	CbGpPWpGaD
Bevantolol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	2.59e-05	0.000214	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—PGR—polycystic ovary syndrome	2.56e-05	0.000212	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—GNAS—polycystic ovary syndrome	2.56e-05	0.000212	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—PLAT—polycystic ovary syndrome	2.44e-05	0.000202	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—GHRL—polycystic ovary syndrome	2.44e-05	0.000202	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—YAP1—polycystic ovary syndrome	2.43e-05	0.000201	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—GAB1—polycystic ovary syndrome	2.4e-05	0.000198	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—GHRL—polycystic ovary syndrome	2.38e-05	0.000197	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—PLAT—polycystic ovary syndrome	2.38e-05	0.000197	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—POMC—polycystic ovary syndrome	2.35e-05	0.000194	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—ATF1—polycystic ovary syndrome	2.32e-05	0.000192	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—POMC—polycystic ovary syndrome	2.3e-05	0.00019	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—INSR—polycystic ovary syndrome	2.29e-05	0.00019	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—ATF1—polycystic ovary syndrome	2.27e-05	0.000188	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	2.27e-05	0.000188	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	2.26e-05	0.000187	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	2.22e-05	0.000184	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—AKT2—polycystic ovary syndrome	2.21e-05	0.000183	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	2.18e-05	0.00018	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—NGFR—polycystic ovary syndrome	2.15e-05	0.000178	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	2.14e-05	0.000177	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—POMC—polycystic ovary syndrome	2.13e-05	0.000176	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—PRL—polycystic ovary syndrome	2.13e-05	0.000176	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—PGR—polycystic ovary syndrome	2.12e-05	0.000176	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—NGFR—polycystic ovary syndrome	2.1e-05	0.000174	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—POMC—polycystic ovary syndrome	2.09e-05	0.000173	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—PRL—polycystic ovary syndrome	2.08e-05	0.000172	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—AKT2—polycystic ovary syndrome	2.05e-05	0.00017	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—ADRB2—polycystic ovary syndrome	2.02e-05	0.000167	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—AKT2—polycystic ovary syndrome	2e-05	0.000166	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—PLAT—polycystic ovary syndrome	1.97e-05	0.000163	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—GHRL—polycystic ovary syndrome	1.97e-05	0.000163	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.9e-05	0.000157	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—ATF1—polycystic ovary syndrome	1.88e-05	0.000156	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—GNAS—polycystic ovary syndrome	1.87e-05	0.000155	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.83e-05	0.000152	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—GNAS—polycystic ovary syndrome	1.83e-05	0.000151	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.83e-05	0.000151	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.78e-05	0.000147	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—NRG1—polycystic ovary syndrome	1.75e-05	0.000145	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.74e-05	0.000144	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—NGFR—polycystic ovary syndrome	1.74e-05	0.000144	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—POMC—polycystic ovary syndrome	1.72e-05	0.000143	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—PRL—polycystic ovary syndrome	1.72e-05	0.000142	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—NRG1—polycystic ovary syndrome	1.71e-05	0.000142	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.66e-05	0.000137	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.63e-05	0.000135	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—GNAS—polycystic ovary syndrome	1.51e-05	0.000125	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—IRS2—polycystic ovary syndrome	1.5e-05	0.000124	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—LEP—polycystic ovary syndrome	1.47e-05	0.000121	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—IRS2—polycystic ovary syndrome	1.47e-05	0.000121	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.44e-05	0.000119	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—LEP—polycystic ovary syndrome	1.43e-05	0.000119	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—NRG1—polycystic ovary syndrome	1.41e-05	0.000117	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—IRS1—polycystic ovary syndrome	1.31e-05	0.000108	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—IRS1—polycystic ovary syndrome	1.28e-05	0.000106	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—POMC—polycystic ovary syndrome	1.26e-05	0.000104	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—INS—polycystic ovary syndrome	1.25e-05	0.000104	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—POMC—polycystic ovary syndrome	1.23e-05	0.000102	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—INS—polycystic ovary syndrome	1.22e-05	0.000101	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—IRS2—polycystic ovary syndrome	1.21e-05	0.0001	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—IGF1—polycystic ovary syndrome	1.21e-05	0.0001	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—AKT2—polycystic ovary syndrome	1.21e-05	0.0001	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—LEP—polycystic ovary syndrome	1.19e-05	9.82e-05	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—IGF1—polycystic ovary syndrome	1.18e-05	9.81e-05	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—AKT2—polycystic ovary syndrome	1.18e-05	9.8e-05	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.15e-05	9.52e-05	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.13e-05	9.31e-05	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—IRS1—polycystic ovary syndrome	1.06e-05	8.76e-05	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—POMC—polycystic ovary syndrome	1.02e-05	8.43e-05	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—INS—polycystic ovary syndrome	1.01e-05	8.39e-05	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—IGF1—polycystic ovary syndrome	9.8e-06	8.11e-05	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—AKT2—polycystic ovary syndrome	9.79e-06	8.11e-05	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	9.31e-06	7.7e-05	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—IL6—polycystic ovary syndrome	9.26e-06	7.67e-05	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—IL6—polycystic ovary syndrome	9.06e-06	7.5e-05	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—VEGFA—polycystic ovary syndrome	7.91e-06	6.55e-05	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—VEGFA—polycystic ovary syndrome	7.74e-06	6.41e-05	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—IL6—polycystic ovary syndrome	7.49e-06	6.2e-05	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.4e-06	5.3e-05	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—IL6—polycystic ovary syndrome	5.47e-06	4.53e-05	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—IL6—polycystic ovary syndrome	5.35e-06	4.43e-05	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—IL6—polycystic ovary syndrome	4.43e-06	3.66e-05	CbGpPWpGaD
